Is Australia positioned to take advantage of biosimilars?

Chee Lim

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)


    Australia currently has a small generic and biosimilar medicine industry despite having a good track record in biomedical research and a sound reputation in producing high quality but small volume biological pharmaceuticals. In recent times, Australia has made incremental changes to its regulation of biosimilars - in patent registration, in the use of commercial confidential information, and in remuneration. These improvements, together with Australia's geographical proximity and strong trade relationship with the Asian biocluster, have positioned Australia to take advantage of potential public cost savings from the increased use of biosimilars.

    Original languageEnglish
    Pages (from-to)184-187
    Number of pages4
    JournalGenerics and Biosimilars Initiative Journal
    Issue number4
    Publication statusPublished - 2014


    • Australia
    • Biosimilars
    • Confidential information
    • Patent
    • Regulation
    • Remuneration


    Dive into the research topics of 'Is Australia positioned to take advantage of biosimilars?'. Together they form a unique fingerprint.

    Cite this